Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
R
Rohit Dhall
High Impact
Department Chairperson
Also affiliated: University of Southern California (2015); University of Hawaiʻi at Mānoa (2024); Barrow Neurological Institute (2012–2017); St. Joseph's Hospital and Medical Center (2012–2017); University of Hawaii System (2024); Georgetown University (2017); Augusta University (2017); Columbia University Irving Medical Center (2024); University of Arkansas Medical Center (2025–2026); University of Rochester Medicine (2017); University of Alabama at Birmingham (2008); National Parkinson's Foundation (2017); Massachusetts General Hospital (2017); Queen's Medical Center (2024); Birmingham VA Medical Center (2008); Centre Hospitalier de l’Université de Montréal (2024); Parkinson's Institute and Clinical Center (2016–2018); Evergreen Health Medical Center (2017); Indiana University School of Medicine (2016); Weill Cornell Medical Center (2024); University of Colorado Anschutz (2017); University of Rochester (2017–2022); Case Western Reserve University (2017); University of Cincinnati (2017); Université de Montréal (2024); Columbia University (2017); University of Toledo (2017); The University of Texas Health Science Center at Houston (2017)
Neurology, College of Medicine
28 h-index
94 pubs
3,693 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Rohit Dhall's research focuses on neurodegenerative disorders, including Parkinson's disease, dementias, dystonia, and tremor. His work investigates novel diagnostics and therapeutics for these conditions, alongside developing and improving care programs for individuals with neurological illnesses. Dhall leads a research group and has published extensively on clinical trials for Parkinson's disease, evaluating treatments such as NLY01, continuous subcutaneous levodopa-carbidopa infusion (ND0612), and IPX203 extended-release carbidopa-levodopa.
His clinical expertise extends to the management of progressive supranuclear palsy and corticobasal syndrome, contributing to consensus statements for care centers. Dhall also studies specific aspects of Parkinson's disease, such as olfactory deficits in the freezing of gait phenotype and the efficacy of vibrotactile stimulation. Additionally, his research includes the safety and efficacy of treatments for Huntington's disease, including valbenazine for chorea and deutetrabenazine.
Dhall serves as Department Chairperson of Neurology at the University of Arkansas for Medical Sciences (UAMS). He also directs the UAMS Parkinson Foundation Comprehensive Care Center and the Cure PSP Center of Care, and co-directs the Multiple Systems Atrophy Center of Excellence at UAMS. His scholarship metrics include an h-index of 29, 99 total publications, and 3,683 total citations.
Research Overview
My clinical expertise in diagnosis and management of Neurodegenerative disorders, including parkinsonism, dementias, dystonia and tremor. My clinical research focuses on developing novel diagnostics and therapeutics, and developing and improving programs delivering care to people living with neurological illness. In addition to serving as Department Chair of Neurology, I direct UAMS' Parkinson Foundation Comprehensive Care Center, and CurePSP Center of Care, and co-direct the Multiple Systems Atrophy Center of Excellence at UAMS.
Metrics
- h-index: 28
- Publications: 94
- Citations: 3,693
Positions
-
Professor and Chair 2023–presentUniversity of Arkansas for Medical Sciences Neurology ORCID
-
Department Chairperson publications 2017–2026University of Arkansas for Medical Sciences Neurology, College of Medicine Institutional directory
-
Professor and Vice Chair, Director of Neurodegenerative disorders, Medical Director Clinical Trials Innovation Unit 2021–2023University of Arkansas for Medical Sciences Neurology ORCID
-
Associate Professor and Director of Neurodegenerative Disorders 2016–2021University of Arkansas Medical Center Neurology ORCID
-
Director of Clinical Trials, Director of NPF Center of Excellence 2015–2016Parkinsons Institute ORCID
-
Associate Professor, Medical Director of Neuromodulation, Director of NPF Center of Excellence 2009–2015Barrow Neurological Institute Neurology ORCID
Selected Publications
-
Consensus expert recommendations for management of urinary dysfunction in Parkinson disease (2026)
-
Levodopa Initiation or Dose Adjustments in TEMPO-4: A 58-Week Open-label Trial of Tavapadon for Treatment of PD (S26.007) (2026)
-
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease (2026)
-
Voice and Speech in Atypical Parkinsonian Disorders (2026)
-
Underlying Tremor Improvement with Consistent Use of Transcutaneous Afferent Patterned Stimulation in Patients with Essential Tremor (2026)
-
A qualitative approach to extract diagnostic patterns of cognitive impairment in Parkinson’s disease (2026)
-
Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease (2025)
-
Transcutaneous Afferent Patterned Stimulation Provides Sustained Benefit in Essential Tremor (PROSPECT Study) (P1-5.002) (2025)
-
Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE‐PD Open‐Label Extension Study (2023)
-
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2023)
-
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's Disease (2023)
-
Impedance trend from a symptomatic perielectrode cystic cavity following deep brain stimulation: illustrative case (2023)
-
Long-term Safety and Efficacy of IPX203 in Parkinson’s Disease Patients with Motor Fluctuations: A 9-Month Open-label Extension Trial (S32.006) (2023)
-
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation (2023)
-
Conversion to Hybrid Deep Brain Stimulation System to Enable Multi‐Contact Fractionation Can be Therapeutic (2022)
Research Interests
Neurodegenerative Disorder; Parkinsonism; Parkinson's Disease; Dementia; Tremor; Dystonia; Chorea Syndromes; Deep Brain Stimulation
Grants & Funding
As listed on this researcher's institutional profile.
- A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (IRB 262548) AEON Biopharma, Inc. via PPD Investigator Services, LLC Principal Investigator
- 58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509) Cerevel Therapeutics, LLC via Syneos Health Principal Investigator
- A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off” Biotie Therapies Inc. Principal Investigator
- A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673) Inhibikase Therapeutics, Inc. via IQVIA, Inc. Principal Investigator
- PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403) Cala Health, Inc Principal Investigator
- A Multicenter, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison...(260930) NeuroDerm, Ltd. via Syneos Health Principal Investigator
- Parkinson’s Foundation 2025-26 Global Care Network Award Parkinson's Foundation Principal Investigator
- An open-label study of nelotanserin in patients with Lewy body dementia who have frequent visual hallucinations or REM sleep behaviors Axovant Sciences, Ltd. Principal Investigator
- exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Patients With Parkinson's Disease (IRB 298952) BlueRock Therapeutics LP via IQVIA, Inc. Principal Investigator
- Parkinson’s Foundation Center Bridge Funding Grant Parkinson's Foundation Principal Investigator
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL) Cerevel Therapeutics, LLC via Syneos Health Principal Investigator
- Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease Patients (IRB 298113) Amneal Pharmaceuticals via Syneos Health Principal Investigator
- Development of the Virtual Unified Huntington Disease Rating Scale (vUHDRS™) (IRB 274554) Huntington Study Group Principal Investigator
- ALS Hoffman Clinic Development Program ALS Association Principal Investigator
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson's Disease (IRB 273929) Sun Pharma Advanced Research Company Limited (SPARC) via Labcorp Principal Investigator
- Parkinson’s Foundation CCC Parkinson's Foundation Principal Investigator
- A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson’s Disease 205998 Impax Laboratories, Inc. Principal Investigator
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis (IRB 273880) Alexion Pharmaceuticals via PPD Investigator Services, LLC Principal Investigator
- A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease (IRB 274317) UCB Biopharma via PAREXEL International LLC Principal Investigator
- A Phase 3, Multicenter, Open-Label Safety Study to Evaluate the Long-Term Safety and Tolerability of SAGE-718 in Participants with Huntington's Disease (IRB 276546) Sage Therapeutics via PAREXEL International LLC Principal Investigator
Collaboration Network
Top Collaborators
Donald G. Grosset
Queen Elizabeth University Hospital (GB)
5 shared publications
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study
Tanya Gurevich
Tel Aviv University (IL)
5 shared publications
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study
Jan Kassubek
Universität Ulm (DE)
5 shared publications
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study
Werner Poewe
Innsbruck Medical University (AT)
5 shared publications
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study
Olivier Rascol
Inserm (FR)
5 shared publications
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study
Monika Rudzińska
Andrzej Frycz Modrzewski Krakow University (PL)
5 shared publications
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study
Alexander Sedkov
Acorda Therapeutics (United States) (US)
5 shared publications
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study
Charles Oh
Acorda Therapeutics (United States) (US)
5 shared publications
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008)
- Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006)
- Long-term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: Interim results of a phase 3 study
- Long-term pulmonary safety of inhaled levodopa in parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study
Tuhin Virmani
University of Arkansas for Medical Sciences
5 shared publications
In database
- Olfactory Deficits in the Freezing of Gait Phenotype of Parkinson's Disease
- Utility of objective gait measures in levodopa‐unresponsive freezing in Parkinson's
- Voice and Speech in Atypical Parkinsonian Disorders
- A qualitative approach to extract diagnostic patterns of cognitive impairment in Parkinson’s disease
- Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease
Casey H. Halpern
University of Pennsylvania (US)
3 shared publications
- Awake versus asleep deep brain stimulation for Parkinson’s disease: a critical comparison and meta-analysis
- Coordinated Reset Vibrotactile Stimulation Induces Sustained Cumulative Benefits in Parkinson’s Disease
- Conversion to Hybrid Deep Brain Stimulation System to Enable Multi‐Contact Fractionation Can be Therapeutic
Tsinsue Chen
Barrow Neurological Institute (US)
3 shared publications
- Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease
- Procedural Variables Influencing Stereotactic Accuracy and Efficiency in Deep Brain Stimulation Surgery
- Electrophysiologic Mapping for Target Acquisition in Deep Brain Stimulation May Become Unnecessary in the Era of Intraoperative Imaging
Zaman Mirzadeh
Barrow Neurological Institute (US)
3 shared publications
- Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease
- Procedural Variables Influencing Stereotactic Accuracy and Efficiency in Deep Brain Stimulation Surgery
- Electrophysiologic Mapping for Target Acquisition in Deep Brain Stimulation May Become Unnecessary in the Era of Intraoperative Imaging
Kristina Chapple
Barrow Neurological Institute (US)
3 shared publications
- Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease
- Procedural Variables Influencing Stereotactic Accuracy and Efficiency in Deep Brain Stimulation Surgery
- Electrophysiologic Mapping for Target Acquisition in Deep Brain Stimulation May Become Unnecessary in the Era of Intraoperative Imaging
Margaret Lambert
Barrow Neurological Institute (US)
3 shared publications
- Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease
- Procedural Variables Influencing Stereotactic Accuracy and Efficiency in Deep Brain Stimulation Surgery
- Electrophysiologic Mapping for Target Acquisition in Deep Brain Stimulation May Become Unnecessary in the Era of Intraoperative Imaging
Holly A. Shill
Barrow Arctic Science Consortium (US)
3 shared publications
- Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease
- Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor
- Transcutaneous Afferent Patterned Stimulation Provides Sustained Benefit in Essential Tremor (PROSPECT Study) (P1-5.002)
Similar Researchers
Based on overlapping research topics
Stephen Brasseux
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Dementia and Cognitive Impairment Research
Neuroscience and Neuropharmacology Research
Sanjeeva Reddy Onteddu
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Neuroscience and Neuropharmacology Research
Disease Mechanisms Research
Hillary Williams
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Neuroscience and Neuropharmacology Research
Disease Mechanisms Research
Tuhin Virmani
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Parkinson's Disease Mechanisms and Treatments
Neuroscience and Neuropharmacology Research
Jorge Luis Rodriguez Lee
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Parkinson's Disease Mechanisms and Treatments
Neuroscience and Neuropharmacology Research
U Thaung Shwe
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Neuroscience and Neuropharmacology Research
Pharmacological Effects and Toxicity Studies